
Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner's seizure reduction and dose-dependent adverse events in adults with focal epilepsy.
Highlights: imaging the temporal dynamics & cellular architecture of seizures in Dravet syndrome, & reducing risk of spontaneous fetal loss.
Studies chosen as the best of epilepsy at AAN 2017 included an examination of the structure of seizures in a mouse model of Dravet syndrome, a look at seizure triggers, the impact of unplanned pregnancy on spontaneous fetal loss, and a review studying the feasibility of extrapolating adjunctive AED efficacy data from adults to a pediatric population.

